Key takeaways: Drug industry leaders have expressed their disapproval of the Texas district court judge’s ruling to invalidate the FDA’s approval of the abortion medication mifepristone. The leaders have argued that the ruling should be reversed, citing decades of scientific evidence and legal precedent. They have called for the ruling to be reversed and for the FDA’s authority to review…
